<bill session="117" type="h" number="7640" updated="2023-03-08T19:58:48Z">
  <state datetime="2022-05-03">REFERRED</state>
  <status>
    <introduced datetime="2022-05-03"/>
  </status>
  <introduced datetime="2022-05-03"/>
  <titles>
    <title type="display">To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").</title>
    <title type="official" as="introduced">To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").</title>
  </titles>
  <sponsor bioguide_id="B001257"/>
  <cosponsors>
    <cosponsor bioguide_id="B001251" joined="2022-05-03"/>
  </cosponsors>
  <actions>
    <action datetime="2022-05-03">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-05-03" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="s" number="4348" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-09-20T17:31:24Z" status="Introduced in House">This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.</summary>
</bill>
